Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Untreated bacterial, fungal or viral skin lesions, rosacea, perioral dermatitis, acne, and plaque psoriasis. Childn <1 yr (oint/cream/lotion/gel/scalp soln); <2 yr (shampoo).
|
|
Special Precautions
Childn. Pregnancy and lactation. Patient Counselling Avoid use w/ occlusive dressing. Avoid contact w/ face (i.e. eyes, nose, mouth), axillae, or groin. Clobetasol foam is flammable, do not smoke during or immediately after application. Monitoring Parameters Monitor for hypothalamic-pituitary-adrenal (HPA) axis suppression through ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test.
|
|
Adverse Reactions
Significant: Hypothalamic-pituitary-adrenal (HPA) axis suppression or hypercorticism (i.e. Cushing's syndrome, hyperglycaemia, glycosuria), contact dermatitis, skin irritation.
Nervous: Numbness of fingers.
CV: Intracranial HTN e.g. bulging fontanelles, headaches, bilateral papilledema.
Dermatologic: Burning and stinging sensation, tingling, cracking, itching, dryness, hypopigmentation, erythema, folliculitis, tenderness, telangiectasia, striae, miliaria, alopecia, pustules and tightening of the scalp.
|
|
Drug Interactions
Increased systemic exposure w/ CYP3A4 enzyme inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplstic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasinox.
|
|
CIMS Class
|
|
ATC Classification
D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.
|
